Market Place
Sourcing Support
BioCryst To Present Evidence Showing Reduced Visits After ORLADEYO®
14 Oct 2024 //
GLOBENEWSWIRE
BioCryst Presents HAE Prophylaxis Data At ACAAI 2024 Meeting
10 Oct 2024 //
GLOBENEWSWIRE
BioCryst Completes pCPA Negotiations for ORLADEYO®
17 Sep 2024 //
GLOBENEWSWIRE
BioCryst Presents New Orladeyo Data At Bradykinin Symposium
06 Sep 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Listing
04 Sep 2024 //
GLOBENEWSWIRE
BioCryst Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
Pint Pharma Announces ORLADEYO Approval For HAE In Peru
09 Jul 2024 //
BUSINESSWIRE
ORLADEYO® (berotralstat) Approved in Peru
09 Jul 2024 //
GLOBENEWSWIRE
KalVista files first oral on-demand HAE drug with FDA
18 Jun 2024 //
PHARMAPHORUM
ORLADEYO Reduces Attack Rates In Normal C1-Inhibitor HAE Patients
02 Jun 2024 //
GLOBENEWSWIRE
Pint Pharma announces Orladeyo approval in Mexico for HAE prevention
14 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Pint Pharma Announces ORLADEYO Approval In Mexico For HAE
13 May 2024 //
BUSINESSWIRE
BioCryst ORLADEYO Real-World Evidence At HAE Conference
09 May 2024 //
GLOBENEWSWIRE
BioCryst`s ORLADEYO Approved in Brazil
17 Apr 2024 //
GLOBENEWSWIRE
Brazil Approves Pint`s ORLADEYO® For HAE In Adults, Kids ?12 Yrs
16 Apr 2024 //
BUSINESSWIRE
BioCryst Presents Data Showing HAE Attack Reductions After Beginning ORLADEYO
23 Feb 2024 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data
05 Feb 2024 //
GLOBENEWSWIRE
BioCryst Announces Full Year 2023 ORLADEYO Net Revenue of $325 Million
05 Jan 2024 //
GLOBENEWSWIRE
BioCryst Announces Publication of Data from Trial of ORLADEYO
19 Dec 2023 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO by the ANMAT in Argentina
29 Nov 2023 //
GLOBENEWSWIRE
BioCryst Presents Data Showing Reduced Attack Rates in Patients with HAE
10 Nov 2023 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO Data at Annual Scientific Meeting
27 Oct 2023 //
GLOBENEWSWIRE
INESSS Recommends Public Reimbursement for BioCryst`s ORLADEYO
18 Sep 2023 //
GLOBENEWSWIRE
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO
19 Jul 2023 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO by Public Health Institute of Chile
22 May 2023 //
GLOBENEWSWIRE
BioCryst Presents New Long-term Data ® (berotralstat)
27 Apr 2023 //
GLOBENEWSWIRE
BioCryst to Present ORLADEYO Data at 2023 American Academy of Annual Meeting
03 Feb 2023 //
GLOBENEWSWIRE
BioCryst Begins Enrollment in Pivotal APeX-P Evaluating ORLADEYO in Patients
26 Jan 2023 //
GLOBENEWSWIRE
BioCryst Announces Preliminary Full Year 2022 ORLADEYO Net Revenue
09 Jan 2023 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO by the Israeli Ministry of Health
28 Nov 2022 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO Data at Annual Scientific Meeting
24 Oct 2022 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
18 Aug 2022 //
GLOBENEWSWIRE
Long-Term Impact of Prophylactic Orladeyo on Hereditary Angioedema
04 Jul 2022 //
PHARMAFILE
BioCryst Announces ORLADEYO Data to be Presented at EAACI Hybrid Congress 2022
22 Jun 2022 //
GLOBENEWSWIRE
BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
07 Jun 2022 //
GLOBENEWSWIRE
BioCryst Says Health Canada has Authorized ORLADEYO for Hereditary Angioedema
06 Jun 2022 //
GLOBENEWSWIRE
BioCryst Presents New Data Following Long-Term Treatment with ORLADEYO
24 Feb 2022 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO Data at 2022 AAAAI Annual Meeting
01 Feb 2022 //
GLOBENEWSWIRE
BioCryst Announces Preliminary Full Year 2021 ORLADEYO Net Revenue and more
10 Jan 2022 //
GLOBENEWSWIRE
BioCryst to Present New ORLADEYO® (berotralstat) Data
26 Oct 2021 //
GLOBENEWSWIRE
NICE Recommends BioCryst’s ORLADEYO® to Prevent Attacks in HAE Patients
16 Sep 2021 //
GLOBENEWSWIRE
BioCryst’s HAE med Orladeyo wins NICE nod
16 Sep 2021 //
PHARMATIMES
BioCryst Announces Approval of ORLADEYO (berotralstat) in United Arab Emirates
09 Sep 2021 //
GLOBENEWSWIRE
BioCryst Applications for ORLADEYO gets accepted by Health Canada and Swissmedic
25 Aug 2021 //
GLOBENEWSWIRE
Berotralstat Effectively Prevents Attacks Related to Hereditary Angioedema
19 Jul 2021 //
FIRSTWORDPHARMA
BioCryst Reports Positive 96-week Data from APeX-2 Showing ORLADEYO
12 Jul 2021 //
GLOBENEWSWIRE
ORLADEYO Data to be Presented at EAACI Hybrid Congress
01 Jul 2021 //
GLOBENEWSWIRE
BioCryst Announces Acceptance of the ORLADEYO Marketing Application in Israel
16 Jun 2021 //
GLOBENEWSWIRE
Japanese NHI price listing triggers $15 M milestone payment to BioCryst
15 Apr 2021 //
BIOSPECTRUMASIA
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™
14 Apr 2021 //
GLOBENEWSWIRE
Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France
11 Mar 2021 //
GLOBENEWSWIRE
BioCryst Submits Marketing Authorization Application for UK of ORLADEYO™
02 Mar 2021 //
GLOBENEWSWIRE
Evrysdi leads latest CHMP recommendations
01 Mar 2021 //
PHARMATIMES
CHMP’s February recommendations: Evrysdi, Jemperli, and a generic
26 Feb 2021 //
RAPS
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat)
25 Feb 2021 //
GLOBENEWSWIRE
Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral
30 Nov 2020 //
GLOBENEWSWIRE
BioCryst Presents Data Showing Sustained Attack Reductions, Improved Patient
13 Nov 2020 //
GLOBENEWSWIRE
MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in UK
30 Oct 2020 //
GLOBENEWSWIRE
New Composition of Matter Patent Allowance Extends Protection for Berotralstat
05 May 2020 //
GLOBENEWSWIRE
